Cargando…
Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19
INTRODUCTION: Tocilizumab, a humanized anti-interleukin-6 receptor (IL-6R) antibody, is recommended for the treatment of severe to critical coronavirus diseases 2019 (COVID-19). However, there were conflicting results on the efficacy of tocilizumab. Therefore, we hypothesized that the differences in...
Autores principales: | Lee, Chan Mi, Kim, Minji, Kang, Chang Kyung, Choe, Pyoeng Gyun, Kim, Nam Joong, Bang, Hyeeun, Cho, Taeeun, Shin, Hyun Mu, Kim, Hang-Rae, Park, Wan Beom, Oh, Myoung-don |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110916/ https://www.ncbi.nlm.nih.gov/pubmed/37081872 http://dx.doi.org/10.3389/fimmu.2023.1110874 |
Ejemplares similares
-
Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity
por: Kang, Chang Kyung, et al.
Publicado: (2022) -
Corrigendum: Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity
por: Kang, Chang Kyung, et al.
Publicado: (2022) -
Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity
por: Kang, Chang Kyung, et al.
Publicado: (2020) -
Amebic Liver Abscess in HIV-infected Patients, Republic of Korea
por: Park, Wan Beom, et al.
Publicado: (2007) -
How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea
por: Park, Do Hyeon, et al.
Publicado: (2022)